BACKGROUND: Despite vaccination, residents of long-term-care facilities (LTCFs) remain at high risk of influenza-related morbidity and mortality. More-effective vaccine options for this population are needed. METHODS: We conducted a single-blinded, randomized, controlled trial comparing high-dose (HD) to standard-dose (SD) inactivated influenza vaccine (IIV) in 205 frail, elderly residents of LTCFs during the 2011-2012 and 2012-2013 influenza seasons. Hemagglutination inhibition (HI) antibody titers were measured at baseline and 30 and 180 days following vaccination. RESULTS:A total of 187 subjects (91%) completed the study. The mean age was 86.7 years. Geometric mean titers (GMTs) were significantly higher (P < .05) at day 30 for HD recipients, compared with SD recipients, for all comparisons except influenza A(H1N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1] during 2012-2013). GMTs for HD and SD recipients during 2011-2012 were as follows: influenza A(H1N1), 78 (95% confidence interval [CI], 45-136) and 27 (95% CI, 17-44), respectively; influenza A(H3N2), 26 (95% CI, 17-40) and 10 (95% CI, 7-15), respectively; and influenza B, 26 (95% CI, 19-35) and 14 (95% CI, 11-18), respectively. During 2012-2013, GMTs for HD and SD recipients were as follows: influenza A(H1N1), 46 (95% CI, 33-63) and 50 (95% CI, 37-67); influenza A(H3N2), 23 (95% CI, 18-31) and 14 (95% CI, 11-18), respectively; and influenza B, 26 (95% CI, 21-32) and 17 (95% CI, 14-22), respectively. GMTs were significantly higher at day 180 for HD recipients, compared with SD recipients, for influenza A(H3N2) in both years (P < .001). CONCLUSIONS: Among frail, elderly residents of LTCFs, HD influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012-2013. CLINICAL TRIALS REGISTRATION: NCT01654224.
RCT Entities:
BACKGROUND: Despite vaccination, residents of long-term-care facilities (LTCFs) remain at high risk of influenza-related morbidity and mortality. More-effective vaccine options for this population are needed. METHODS: We conducted a single-blinded, randomized, controlled trial comparing high-dose (HD) to standard-dose (SD) inactivated influenza vaccine (IIV) in 205 frail, elderly residents of LTCFs during the 2011-2012 and 2012-2013 influenza seasons. Hemagglutination inhibition (HI) antibody titers were measured at baseline and 30 and 180 days following vaccination. RESULTS: A total of 187 subjects (91%) completed the study. The mean age was 86.7 years. Geometric mean titers (GMTs) were significantly higher (P < .05) at day 30 for HD recipients, compared with SD recipients, for all comparisons except influenza A(H1N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1] during 2012-2013). GMTs for HD and SD recipients during 2011-2012 were as follows: influenza A(H1N1), 78 (95% confidence interval [CI], 45-136) and 27 (95% CI, 17-44), respectively; influenza A(H3N2), 26 (95% CI, 17-40) and 10 (95% CI, 7-15), respectively; and influenza B, 26 (95% CI, 19-35) and 14 (95% CI, 11-18), respectively. During 2012-2013, GMTs for HD and SD recipients were as follows: influenza A(H1N1), 46 (95% CI, 33-63) and 50 (95% CI, 37-67); influenza A(H3N2), 23 (95% CI, 18-31) and 14 (95% CI, 11-18), respectively; and influenza B, 26 (95% CI, 21-32) and 17 (95% CI, 14-22), respectively. GMTs were significantly higher at day 180 for HD recipients, compared with SD recipients, for influenza A(H3N2) in both years (P < .001). CONCLUSIONS: Among frail, elderly residents of LTCFs, HD influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012-2013. CLINICAL TRIALS REGISTRATION: NCT01654224.
Authors: Carlos A DiazGranados; Andrew J Dunning; Emilia Jordanov; Victoria Landolfi; Martine Denis; H Keipp Talbot Journal: Vaccine Date: 2012-12-20 Impact factor: 3.641
Authors: A M Palache; W E Beyer; M J Sprenger; N Masurel; S de Jonge; A Vardy; B Charpentier; J Noury; W C van Beek; R J Borst Journal: Vaccine Date: 1993 Impact factor: 3.641
Authors: Rick A Bright; Marie-jo Medina; Xiyan Xu; Gilda Perez-Oronoz; Teresa R Wallis; Xiaohong M Davis; Laura Povinelli; Nancy J Cox; Alexander I Klimov Journal: Lancet Date: 2005-09-22 Impact factor: 79.321
Authors: John J Treanor; Gilbert M Schiff; Robert B Couch; Thomas R Cate; Rebecca C Brady; C Mhorag Hay; Mark Wolff; Dewei She; Manon M J Cox Journal: J Infect Dis Date: 2006-03-28 Impact factor: 5.226
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Jin Hyang Kim; H Keipp Talbot; Margarita Mishina; Yuwei Zhu; Jufu Chen; Weiping Cao; Adrian J Reber; Marie R Griffin; David K Shay; Sarah M Spencer; Suryaprakash Sambhara Journal: Vaccine Date: 2016-07-26 Impact factor: 3.641
Authors: Jonathan M Raviotta; Kenneth J Smith; Jay DePasse; Shawn T Brown; Eunha Shim; Mary Patricia Nowalk; Angela Wateska; Glenson S France; Richard K Zimmerman Journal: Vaccine Date: 2017-09-07 Impact factor: 3.641
Authors: Stefan Gravenstein; H Edward Davidson; Lisa F Han; Jessica A Ogarek; Roshani Dahal; Pedro L Gozalo; Monica Taljaard; Vincent Mor Journal: Hum Vaccin Immunother Date: 2017-12-14 Impact factor: 3.452
Authors: Nathalie Loeb; Melissa K Andrew; Mark Loeb; George A Kuchel; Laura Haynes; Janet E McElhaney; Chris P Verschoor Journal: Open Forum Infect Dis Date: 2020-04-24 Impact factor: 3.835
Authors: A Gil de Miguel; E Redondo Marguello; J Díez Domingo; R Ortiz de Lejarazu; F Martinón Torres Journal: Rev Esp Quimioter Date: 2020-06-09 Impact factor: 1.553